 CNS Pharmaceuticals, Inc., Nasdaq: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has received notification from Nasdaq that trading in the Companys common stock will resume on Thursday, May 28, 2020. 